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https://doi.org/10.1016/j.stemcr.2017.10.024SUMMARYReporter cell lines have already proven valuable in identifying, tracking, and purifying cardiac subtypes and progenitors during differen-
tiation of human pluripotent stem cells (hPSCs). We previously showed that chick ovalbumin upstream promoter transcription factor II
(COUP-TFII) is highly enriched in human atrial cardiomyocytes (CMs), but not ventricular. Here, we targetedmCherry to the COUP-TFII
genomic locus in hPSCs expressing GFP from the NKX2.5 locus. This dual atrial NKX2.5EGFP/+-COUP-TFIImCherry/+ reporter line allowed
identification and selection of GFP+ (G+)/mCherry+ (M+) CMs following cardiac differentiation. These cells exhibited transcriptional and
functional properties of atrial CMs, whereas G+/M CMs displayed ventricular characteristics. Via CRISPR/Cas9-mediated knockout, we
demonstrated that COUP-TFII is not required for atrial specification in hPSCs. This new tool allowed selection of human atrial and
ventricular CMs from mixed populations, of relevance for studying cardiac specification, developing human atrial disease models,
and examining distinct effects of drugs on the atrium versus ventricle.INTRODUCTION
Human pluripotent stem cells (hPSCs) can differentiate to
all cells of the human body. This has resulted in high expec-
tations for applications in regenerative medicine, drug
discovery, disease modeling in vitro, and developmental
biology (Keller, 2005). Primary human cardiomyocytes
(CMs) are extremely difficult to obtain from biopsies and
to maintain in culture, so that hPSC-derived CMs (hPSC-
CMs) have been rapidly implemented as an alternative
not only in disease modeling in vitro but also in pre-clinical
drug testing and safety pharmacology (Beqqali et al., 2009;
Braam et al., 2010; Maddah et al., 2015; van Meer et al.,
2016; Sala et al., 2016). Despite substantial improvements
in the efficiency of hPSC differentiation to CMs during
the last decade, the majority of directed cardiac differentia-
tionprotocols yieldheterogeneousCMpopulations, largely
composed of ventricular CMs (Mummery et al., 2012).
Recently, we demonstrated efficient generation of atrial
CMs from human embryonic stem cells (hESCs) (Devalla
et al., 2015). These hESC-derived atrial CMs (hESC-AM),
resemble human fetal atrial CMs at themolecular and func-
tional level and have already proven to be a predictive and
reliable pre-clinicalmodel for atrial selective pharmacology
(Devalla et al., 2015). Although hESC-AMs represented the
majority ofCMs (approximately 85%) inour directeddiffer-
entiationprotocol, other cardiac subtypes (mostly ventricu-
lar CMs with less than 1% of nodal cells) were also present.Stem Cell Report
This is an open access article under the CTo select hESC-AM populations and study their differen-
tiation in vitro, we generated a fluorescent atrial hESC re-
porter line. Previously, we have shown that chick
ovalbumin upstream promoter transcription factors I and
II (COUP-TFI and II or NR2F1 and NR2F2) are highly ex-
pressed in retinoic acid (RA)-induced hESC-AMs, but not
in ventricular CMs (hESC-VMs) (Devalla et al., 2015). In
both the human fetal and adult heart, COUP-TFI and II
are expressed in myocardial cells of the atria, but not the
ventricles (Devalla et al., 2015). COUP-TFs belong to the
steroid/thyroid hormone receptor superfamily, which
shares high homology with retinoid and RA receptor
subfamily members (Tsai and Tsai, 1997). Along with
evolutionarily conserved protein-encoding sequences, the
expression of COUP-TFII is also broadly identical inmouse,
chick, zebrafish, frog, and Drosophila (Tsai and Tsai, 1997).
During murine heart development, COUP-TFII is first
detected in the visceral mesoderm and sinus venosus,
then progresses to the common atrium, and becomes
restricted to CMs of the atrial chambers at later stages of
development (Pereira et al., 1999; Wu et al., 2013). This in-
dicates that COUP-TFII is an important atrial-enriched
transcription factor and prompted us to develop an atrial
hESC reporter line using CRISPR/Cas9 genome-editing
technology to insert sequences encoding the red-fluores-
cent protein mCherry into one allele of the genomic
COUP-TFII locus. Since COUP-TFII expression is not
confined to CMs, but is also expressed in othermesodermals j Vol. 9 j 1765–1779 j December 12, 2017 j ª 2017 The Authors. 1765
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cell types (for example, venous endothelial cells, skeletal
muscle, and kidneys) (Lee et al., 2004; You et al., 2005; Yu
et al., 2012), as well as endodermal (for example, liver
and pancreas) (Zhang et al., 2002) and some ectodermal
derivatives (cerebellum, eye, and ear) (Kim et al., 2009;
Tang et al., 2010, 2005), we chose the well-established hu-
man cardiac NKX2.5EGFP/+ reporter (Elliott et al., 2011) to
develop a unique dual reporter line that would allow iden-
tification and purification of hESC-AMs. Transcriptional
and functional analysis of sorted GFP+ (G+)/mCherry+
(M+) double-positive CMs clearly demonstrated their atrial
identity, whereas G+/M CMs belonged to the ventricular
lineage. In addition, we found that complete loss of
COUP-TFII did not affect the differentiation toward AMs,
based on both molecular and functional analysis. Purifica-
tion of hESC-AMs will likely be important for optimization
and standardization of assays in cardiac drug screening and
modeling atrial diseases, such as atrial fibrillation, and un-
derstanding underlying molecular mechanisms for atrial
specification and disease.RESULTS
Generation of a Fluorescent Dual Reporter by CRISPR/
CAS9-Mediated Targeting of COUP-TFII in hESC-
NKX2.5-GFP
To generate an atrial hESC reporter line, we inserted se-
quences encoding the red fluorophore mCherry into the
genomic locus of COUP-TFII (NR2F2) in the hESC
NKX2.5EGFP/+ cardiac reporter line (NKX-GFP) (Elliott
et al., 2011) using CRISPR/Cas9-mediated genome editing.
Two different single-guide RNAs (sgRNAs) were designed to
direct double-strand breaks within exon 1 of COUP-TFII
(sgRNA 1 and 2) (Figure 1A). NKX-GFP hESCs were trans-
fected with the COUP-TFII-mCherry targeting vector and
one of the sgRNAs co-expressed from the Cas9 vector (Fig-
ures 1B and 1C). After antibiotic selection, the excision of
the blasticidin-resistance gene was mediated using flippase
site-specific recombination (Figure 1C). Correctly targeted
clones displayed a 0.8 kb PCR product following screening
of the 50 end and a 2.9 kb product (1.7 kb after blasticidin
excision) of the 30 end (Figure 1D). Following clonal selec-
tion by fluorescence-activated cell sorting (FACS), correct
targeting of the subclones as well as excision of the blastici-
din-resistance cassette was reconfirmed by PCR. In addi-
tion, a PCR screen was performed to determine whether
mCherry was inserted into one or both COUP-TFII alleles
(Figure 1D). For subclones in which mCherry was monoal-
lelic targeted, the genomic integrity of the wild-type (WT)
COUP-TFII allele was confirmed by Sanger sequencing of
the PCR product. Following sequencing, we identified
that, in all mCherry monoallelic-targeted clones from1766 Stem Cell Reports j Vol. 9 j 1765–1779 j December 12, 2017sgRNA 1 and 2, the other allele possessed either insertions
or deletions in the COUP-TFII coding sequence. Conse-
quently, none of the resulting COUP-TFII-mCherry
knockin clones were heterozygous for both mCherry and
COUP-TFII.
To produce a COUP-TFIImCherry/+ hESC line, we designed
a strategy to correct a 9 bp deletion in one of the subclones
(Figure 1E). sgRNA 3 (Figure 1F) was designed to specifically
anneal to the deleted region, while a single-stranded DNA
(ssDNA) oligonucleotide (ssDNA oligo) containing part of
the WT COUP-TFII genomic sequence (sequence available
in the Supplemental Experimental Procedures) was used
as the template tomediate gene repair throughhomologous
recombination. The sgRNA, alongwithCas9 and the ssDNA
oligo were transfected into COUP-TFII-targeted hESCs that
carried the 9 bp deletion before subcloning (Figures 1E and
1G).Nooff-target effects by the sgRNAsweredetected at any
of the top four analyzed in-silico-predicted genomic sites in
all lines tested (Figure S1). Undifferentiated cells expressed
the stemcellmarker TRA-1-60 (Figure S2A) andkaryotyping
demonstrated no chromosomal abnormalities in the genet-
ically modified hESCs (Figure S2B).
NKX2.5EGFP/+-COUP-TFIImCherry/+ hESCs Robustly
Express mCherry upon Induction with RA
To initiate cardiac differentiation, hESCs from the cor-
rected NKX2.5EGFP/+-COUP-TFIImCherry/+ dual reporter
line, hereafter called ‘‘COUP-red’’, were differentiated to-
ward mesoderm by adding growth factors activin-A,
BMP4, VEGF, SCF, and the GSK-3 inhibitor Chir99021
after the formation of aggregates by centrifugation (spin-
embryoid bodies [spin-EBs]) (Figure 2A) as described previ-
ously (Devalla et al., 2015). For efficient directed cardiac dif-
ferentiation towards the atrial fate, 1 mM RA was added to
the EBs from day 4 to day 7 without additional medium
changes (Devalla et al., 2015). In agreement with previous
reports demonstrating that RA induces COUP-TFII expres-
sion (Kruse et al., 2008), only upon treatment with RA
could mCherry fluorescence be detected in a subset of cells
36 hr (day 6) after RA addition; this was followed later at
day 14 by a broader and higher mCherry fluorescence
intensity (Figure 2B). As expected, only a small subpopula-
tion of cells in control differentiation (CT) (no RA) dis-
played mCherry fluorescence, which did not overlap with
GFP (Figures 2B and 2C). Only in the presence of RA did
themajority of cells robustly express mCherry in combina-
tion with increased GFP fluorescence (Figure 2B), suggest-
ing that these cells co-expressed transcription factors
COUP-TFII and NKX2.5. In contrast, in CT cultures, the
majority of M+ cells were negative for GFP (NKX2.5) (Fig-
ure 2B).We used flow cytometry to quantify the percentage
of GFP- and mCherry-expressing cells. In agreement with
our previous findings, more than 90% of the RA-treated
Figure 1. CRISPR/Cas9-Mediated Knockin
of mCherry into COUP-TFII
(A) Location and sequence of single-guide
RNAs (sgRNAs) 1 and 2 in the COUP-TFII
locus.
(B) Schematic representation of the
CRISPR/Cas9 plasmid-based targeting and
dual-selection protocol.
(C) Schematic overview of wild-type (WT)
COUP-TFII, COUP-TFII-mCherry targeting
construct, and the resulting targeted (first
allele) and WT COUP-TFII (second allele)
alleles with forward (FWD) and reverse (RV)
primer binding sites for screening.
(D) PCR screen to identify targeted clones:
Upper panel: 30 end screen and confirmation
of excision of the blasticidin-resistance
cassette in 1, 2, 4, 5, and 6, but not 3
(targeted, but blasticidin-resistance
cassette still present). Middle panel: 50 end
screen shows that clones 1–3, and 5 and 6,
were targeted at the 50 end. Lower panel:
screen to determine if heterozygous (clones
2, 3, 4, and 6) or homozygous (clones 1 and
5) mCherry knockin occurred.
(E) Schematic representation of the CRISPR/
Cas9-mediated correction using a WT COUP-
TFII single-stranded oligonucleotide (ssDNA
oligo).
(F) Sequence corresponding to the 9 bp
deletion in the COUP-TFII locus along with
the annealing sites for sgRNA 3 designed to
repair the deletion.
(G) Sanger sequencing confirming correc-
tion of the second COUP-TFII allele from the
COUP-red clone after correction.
See also Figures S1 and S2.cells were mCherry positive at day 14 (Figures 2C and 2D),
and approximately half of these cells also expressed GFP.
On the other hand, the majority of G+ cells were mCherry
positive (90% based on G+/M+: 41% ± 2%, G/M+: 52% ±
3%, G+/M: 4% ± 1%, G/M: 4% ± 1%; n = 4; mean ±
SEM) (Figures 2C and 2D). By contrast, cells from CT differ-
entiation displayed a high percentage of G+/M cells
together with lower percentages of the other fractions
(G+/M+: 12% ± 1%, G/M+: 14% ± 2%, G+/M: 61% ±
4%, G/M: 13% ± 2%; n = 4; mean ± SEM) (Figures 2C
and 3D).COUP-TFII RNA and protein levels could be identified in
RA-treated samples but not in CT. As expected, protein
COUP-TFII levels in the heterozygous COUP-red reporter
were reduced by half (Figure S3D). Expression of the
COUP-TFII homolog COUP-TFI was not affected
(Figure S3E).
TheCOUP-TFII Reporter Reliably Identifies Functional
Human Atrial Cardiomyocytes
Both cardiac subpopulations expressed cardiac troponin
(Figures 2E and 2F) and, after approximately 10 days ofStem Cell Reports j Vol. 9 j 1765–1779 j December 12, 2017 1767
Figure 2. Characterization of the Dual
Human NKX2.5EGFP/+-COUP-TFIImCherry/+
Stem Cell Line (COUP-red) as Atrial
Reporter
(A) Atrial-directed pin-embryoid body
(spin-EB) protocol and treatment with
retinoic acid (RA).
(B) mCherry expression together with GFP
and bright-field (BF) images at D7 and D14
of differentiation in RA and control (CT)
differentiations. Scale bar, 100 mm.
(C) Representative flow cytometry plots
depicting the percentage of GFP-positive
(G+) or mCherry (M+) cells at D14 of differ-
entiation in RA or CT differentiations.
(D) Averaged G/M percentage calculated
from four independent differentiations
(n = 4): RA condition (G+/M+: 41% ± 2%,
G/M+: 52% ± 3%, G+/M: 4% ± 1%,
G/M: 4% ± 1%) versus CT (G+/M+: 12% ±
1%, G/M+: 14% ± 2%, G+/M: 61% ± 4%,
G/M: 13% ± 2%). Data are displayed as
means ± SEM
(E) Relative mRNA expression of cardiac
troponin (TNNT2) in sorted G/M populations
at day 20 of differentiation. Data are dis-
played as means ± SEM; *p < 0.05.
(F) Immunostaining of cardiac troponin
(cTnI) together with endogenous GFP
expression and DAPI as nuclear staining in
unsorted cultures after dissociation and re-
plating. Scale bars, 25 mm (left), 2.5 mm
(right).
See also Figure S3.differentiation, spontaneously contracting cells appeared
in RA and in CT differentiations of COUP-red (Movies S1
and S2).
Since G+/M+ double-positive cells were expected to have
an atrial identity and G+/M cells ventricular, we charac-
terized the functional phenotype of sorted CMs by evalu-
ating their action potentials (APs) by patch-clamp
methodology (Figure 3A; raw data available in Table S1).
In agreement with our previous study, typical AP traces
stimulated at 1 Hz showed faster repolarization in
RA-treated G+/M+ CMs compared with non-treated1768 Stem Cell Reports j Vol. 9 j 1765–1779 j December 12, 2017G+/M CT CMs (Figure 3B). Whereas maximal diastolic
potential, maximal AP amplitude (APAmax), and maximal
AP upstroke velocity (dV/dtmax) did not differ between
populations, G+/M+ CMs from RA-treated differentiations
exhibited marked reduction in average AP plateau ampli-
tude (APAplat) and AP duration at 20%, 50%, and 90%
repolarization compared with G+/M CMs (Figure 3C).
Most importantly, despite some biological variation in
APAplat of single CMs, none of the G
+/M CMs exhibited
atrial AP properties, and, vice versa, none of G+/M+ CMs
had a ventricular phenotype (Figure 3C). Also at higher
Figure 3. M+ COUP-red CMs Exhibit Atrial Proper-
ties
(A) Analyzed AP parameters.
(B) Representative AP of G+/M+ CMs generated from
RA-treated and G+/M CMs from CT differentiations
at 1 Hz stimulation.
(C) Averaged maximum diastolic potential (MDP),
maximum AP amplitude (APAmax) and AP plateau
amplitude (APAplat), maximum upstroke velocity
(dV/dtmax), and AP duration at 20%, 50%, and 90%
repolarization (APD20, APD50, and APD90). Scatter-
plot depicting the APAplat of single CMs and calcu-
lated median from RA and CT conditions. n = 21 cells
for RA G+/M+ and n = 18 cells for CT G+/M; from 3
independent differentiations. Data are displayed as
means ± SEM; *p < 0.05.
(D) Typical AP traces stimulated at different fre-
quencies.
(E) Transcriptional profiling of selected atrial or
ventricular-specific genes by qPCR of G+/M+ and
G/M+ fractions from RA differentiations compared
with G+/M and G/M fractions from CT differen-
tiations at D20 of differentiations (n = 4). Data are
displayed as means ± SEM; *p < 0.05.
(F) Genome-wide transcriptional profiling by mi-
croarray. Heatmaps to display the fold difference of
selected atrial- and ventricular-enriched transcripts
in RA-treated G+/M+ and CT G+/M from COUP-red at
a threshold of 2-fold difference.
See also Figure S3.
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pacing frequencies, cells maintained their characteristic
AP properties (Figure 3D).
As expected, quantitative PCR (qPCR) of sorted G+/M+
CMs showed increased mRNA expression of the atrial
markers NPPA and PITX2 and downregulation of the ven-
tricular gene IRX4 compared with G+/M CMs (Figure 3E).
Moreover, G+/M+ CMs were characterized by enhanced
expression of the atrial ion channel genes, potassium
voltage-gated channel subfamily A member 5 (KCNA5), potas-
sium voltage-gated channel subfamily J members 3 (KCNJ3),
and 5 (KCNJ5) (Figure 3E). In agreement with the qPCR
data, human whole-genome-wide transcriptional profiling
of G+/M+ CMs from RA and G+/M CMs from CT,
demonstrated upregulation of atrial-enriched transcripts,
including VSNL1, PITX2, MYH11, ISL1, NR2F1 and 2,
KCNA5, and NPPA, in hESC-AMs (G+/M+ CMs), and
enhanced expression of ventricular genes, such as IRX4,
HEY2, MYH7, NAV1, PLCXD3, VCAM1, HAND1, and
MYL2 in hESC-VMs (G+/M CMs) (Figure 3F). Together,
functional and transcriptional analysis confirmed atrial
identity of G+/M+ CMs (hESC-AMs) and ventricular iden-
tity of G+/M CMs (hESC-VMs).
Identity of mCherry-Positive Non-CMs
Besides efficient identification and selection of hESC-AMs
and hESC-VMs, RA-treated cultures of the dual COUP-red
reporter also clearly indicated a NKX2.5-negative, COUP-
TFII-positive (G/M+) (presumably non-CM) subpopula-
tion. Besides in atrial CMs, COUP-TFII is also expressed
in the epicardium (Lin et al., 2012), smooth muscle, and
venous endothelial cells (You et al., 2005). Indeed, human
whole-genome-wide transcriptional analysis by microar-
ray showed more than 600 transcripts with 2-fold upregu-
lation in G/M+ compared with G+/M+ cells; gene
ontology (GO) identified enrichment of several GO terms,
including cardiovascular system and blood vessel develop-
ment, that had the highest GO enrichment scores (Fig-
ure S3A), as well as terms related to the differentiation of
epicardial cells (Figure S3B). Quantification by flow cytom-
etry at day 13 of differentiation showed that 26% of
G/M+ cells expressed the endothelial cell, smooth mus-
cle, and fibroblast marker CD90 (Thy-1), with 4% of cells
double-positive for CD90 and the endothelial marker
platelet endothelial cell adhesion molecule (PECAM or
CD31) (Figure S3B). In agreement, a subpopulation (4%)
of G/M+ cells co-expressed the endothelial markers
CD31 and VE-cadherin (CD144) together with a large
(47%) intermediate population expressing either CD31
(10%) or CD144 (37%) (Figure S3B). However, at day 21,
the majority of non-CMs (both M+ and M) expressed
SMA mRNA (encoded by smooth muscle ACTA2) and pro-
tein, while we did not observe PECAM protein expression,
which suggested that the majority of G/M+ subpopula-1770 Stem Cell Reports j Vol. 9 j 1765–1779 j December 12, 2017tion belong to the smooth muscle cell lineage at this stage
(Figure S3C).
Since COUP-TFII is also expressed in many endodermal
derivatives, we studied the endodermal marker a-fetopro-
tein (AFP). Only very few cells expressed AFP suggesting
that cells with endodermal identity constituted a very
minor subpopulation in both RA as well as CT cultures
(Figure S3B).
CRISPR/Cas9-Mediated Knockout of COUP-TFII in
hESCs
After establishing that the COUP-red dual reporter line is
useful for the selection of atrial and ventricular CMs, we
determined whether COUP-TFII is required for specifica-
tion of the atrial lineage during in vitro differentiation.
Although COUP-TFII has been shown as essential for atrial
specification in twomouse models (Pereira et al., 1999; Wu
et al., 2013), information on its role in atrial patterning of
the human heart is limited. Following insertion of
mCherry into the COUP-TFII genomic locus of one allele,
we identified different disrupting genotypic modifications
on the second COUP-TFII allele which introduced a prema-
ture stop codon, yielding two independent cell lines with
complete knockout (hereafter called ‘‘COUP-KO 1’’ gener-
ated with sgRNA 1 and ‘‘COUP-KO 2’’ independently
generated with sgRNA 2) (Figure S4).
We then attempted to differentiate the COUP-KO cell
lines to the atrial lineage by treatment with RA. As for
RA and CT differentiation of the COUP-red reporter,
both COUP-KO cell lines rapidly upregulated mCherry
upon RA treatment starting at day 6 (Figure S5A), and
robustly expressed mCherry in majority of cells by day
14 of differentiation, whereas CT differentiations yielded
predominantly G+/M populations (Figures 4A and S5B).
In flow cytometry, both RA and CT differentiation of
COUP-KO lines resulted in a similar distribution of G/M
populations compared with the COUP-red reporter (Fig-
ures 4B, 4C, S5C, and S5D; Table 1). Importantly, we
observed no obvious differences in onset or overall per-
centages of GFP in RA and CT differentiation from
COUP-KO compared with WT NKX-GFP cells with two
functional COUP-TFII alleles (Figures 4B, 4C, S5C, and
S5D; Table 1). Complete knockout of COUP-TFII protein
was confirmed by western blot in differentiated CMs
from both COUP-KO lines, whereas there was prominent
expression of COUP-TFII in RA-treated WT NKX-GFP cells
(Figures 4D and 4E).
COUP-KO hESCs Differentiate to Functional Atrial
Cardiomyocytes
Much like the directed cardiac differentiation of WT
NKX-GFP and COUP-red hESCs, RA and CT cells of both
COUP-KO lines expressed similar levels of cardiac troponin
Figure 4. Characterization of COUP-KO
Lines
(A) mCherry overlapping with GFP and bright-
field (BF) images at D7 and D14 of differenti-
ation in RA or CT differentiations from WT
NKX-GFP or COUP-KO cells from subclone COUP-
KO 1. Scale bars, 100 mm.
(B) Representative flow cytometry plots de-
picting the percentage of GFP-positive (G+)
and mCherry (M+) cells at D7 and D14 of dif-
ferentiation in RA or CT samples from WT NKX-
GFP or COUP-KO 1.
(C) Averaged G/M percentage calculated from
three independent differentiations (n = 3) at
day 7 of differentiation in RA (G+/M+, 18% ±
6%; G/M+, 61% ± 10%; G+/M, 7% ± 3%;
G/M, 15% ± 3%) and CT (G+/M+, 8% ± 2%;
G/M+, 8% ± 3%; G+/M, 38% ± 3%; G/M,
46% ± 4%) and at day 14 in RA (G+/M+, 46% ±
2%; G/M+, 50% ± 1%; G+/M, 4% ± 2%;
G/M, 2% ± 1%) and CT (G+/M+, 18% ± 2%;
G/M+, 26% ± 2%; G+/M, 46% ± 2%; G/M,
10% ± 1%), together with WT NKX-GFP cells
(D7, CT G+/M+, 5% ± 3%; G+/M 65% ± 3%;
G/M 30% ± 3%; G/M+, 1% ± 1%; RA G+/M+,
4% ± 1%; G+/M 48% ± 4%; G/M 45% ±
4%; G/M+, 2% ± 1%; D14, CT G+/M+, 3% ±
1%; G+/M 49% ± 3%; G/M 48% ± 3%;
G/M+, 0% ± 0%; RA G+/M+, 4% ± 1%; G+/M
15% ± 4%; G/M 81% ± 4%; G/M+, 1% ±
1%). n = 3 independent differentiations;
mean ± SEM.
(D) mRNA expression of COUP-TFII in COUP-KO
1 cells at day 14 of differentiation (n = 4 in-
dependent differentiations; mean ± SEM; *p <
0.05).
(E) Validation of complete knock out of COUP-
TFII expression by western blot in unpurified
differentiated CMs from RA and CT differenti-
ations from COUP-KO cells compared with WT
NKX-GFP cells.
(F) mRNA expression of cardiac troponin
(TNNT2) in differentiated CMs from RA and CT
differentiations from COUP-KO 1 and WT NKX-
GFP cells (n = 4 independent differentiations).
See also Figures S4, S5, and S8.
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Table 1. Comparison of G/M Percentages in RA and CT
Differentiation between Different Cell Lines at Day 14 of
Differentiation
Line G+/M+ (%) G+/M– (%) G/M+ (%) G/M– (%)
WT NKX-GFP
RA (n = 3)
– 52 ± 5 – 47 ± 5
COUP-red
RA (n = 4)
41 ± 2 4 ± 1 52 ± 3 4 ± 1
COUP-KO 1
RA (n = 3)
46 ± 2 3 ± 2 50 ± 1 2 ± 1
COUP-KO 2
RA (n = 2)
37 ± 5 5 ± 2 56 ± 4 3 ± 2
WT NKX-GFP
CT (n = 3)
– 70 ± 5 – 30 ± 4
COUP-red
CT (n = 4)
12 ± 1 61 ± 4 14 ± 2 13 ± 2
COUP-KO 1
CT (n = 3)
18 ± 2 46 ± 4 26 ± 2 10 ± 1
COUP-KO 2
CT (n = 2)
18 ± 4 42 ± 4 27 ± 4 14 ± 3
Data are displayed as average percentages ± SEM from n = independent dif-
ferentiations.(TNNT2) (Figure 4F) and developed into functional con-
tracting CMs within 10 days (Movies S3 and S4).
To establish the atrial identity of G+/M+ CMs, we
analyzed sorted cells by perforated patch clamp and
compared them with WT NKX-GFP CMs (Figure 5A; raw
data available in Table S1). Average AP characteristics of
RA-treated G+/M+ and CT G+/M CMs from both COUP-
KO lines were identical to their equivalents from WT
NKX-GFP cells (Figure 5B). G+/M+ CMs from RA-treated
COUP-KO differentiations showed a significant reduction
in APAplat and AP duration compared with G
+/M CMs
despite functional loss of COUP-TFII (Figure 5B). This was
consistent with functional expression of atrial-specific
potassium ion channels, which are responsible for the
fast repolarization in atrial, but not ventricular CMs. Inter-
estingly, RA-treated and CT G+/M+ CMs from COUP-KO 1
and COUP-red lines exhibited comparable atrial AP charac-
teristics, suggesting that COUP-TFII deletion did not affect
atrial differentiation in the RA, as well as in the CT condi-
tion (Figure S6A). Similarly, G+/M CMs from CT and RA
displayed typical ventricular characteristics (Figure S6B).
Transcriptional Profiling ofWT,COUP-KO, andCOUP-
red Cardiomyocytes
Since we did not observe functional differences between
COUP-KO CMs and the original WT NKX-GFP CMs, we
next studied their molecular profiles by qPCR on day 14 of1772 Stem Cell Reports j Vol. 9 j 1765–1779 j December 12, 2017differentiation. CMs were FACS selected from both COUP-
KO lines (G+/M+ from RA-treated and G+/M from CT sam-
ples) and compared with G+ WT NKX-GFP CMs from
RA-treated and CT samples (approximately 85% atrial in
RAand largely ventricularCMs inCT). Similar toCMsdiffer-
entiated from the COUP-red reporter or WT NKX-GFP
hESCs, RA-treated G+/M+ CMs from the COUP-KO lines ex-
hibited enhanced expression of atrial-enriched PITX2 and
atrial potassium ion channel genes KCNA5 and KCNJ3,
along with simultaneous downregulation of the ventricular
marker IRX4 (Figures 6A, S5E, and S5F). In contrast, KCNJ5
expression was downregulated in RA-treated G+/M+ CMs
from COUP-KO hESCs compared with their corresponding
RA-treated equivalents from WT NKX-GFP or COUP-red
cells (Figures 6A and S5E). To determine whether there
were additional transcriptional changes, we quantified the
expression of genes previously reported to be targets of
COUP-TFII. In comparison with G+/M CMs (ventricular),
G+/M+ COUP-KO CMs (atrial) exhibited increased expres-
sion of the atrial-enriched gap junction gene GJA5 and the
atrial transcription factors HEY1 and TBX5, as well as
decreased expression of ventricular-enriched genes, MYL2
and HEY2 (Figures 6B, S5E, and S5F). Importantly, these
expression levelswere comparablewith levels of these genes
in RA and CT differentiations of the WT NKX-GFP line.
Since knockout of COUP-TFII did not apparently result in
major differences in expression of COUP-TFII target genes,
we next carried out human whole-genome transcriptional
profiling by microarray hybridization, for which sorted
RA-treated and CT CMs from both COUP-KO and WT
NKX-GFP lines in week 3 of differentiation were used. In
agreement with our qPCR data, hierarchical clustering
identified two clusters of RA-treated and CT CMs indepen-
dent of the line (KO, COUP-red, or WT) from which they
were derived (Figure 6C). As expected, we observed upregu-
lation of atrial transcripts in RA-treated CMs (including
VSNL1, PITX2, MYH11, ISL1, and NR2F1 and 2) and
increased expression of ventricular transcripts in CT CMs
(including IRX4, HEY2, MYH7, NAV1, PLCXD3, and
VCAM1) from all three lines independent of their COUP-
TFII genotype, suggesting that knockout of COUP-TFII
had little effect on induction or repression of an atrial or
ventricular-specific transcriptional program in hESC-CMs
(Figure 6D; Table S3). The majority of affected genes which
had a clear atrial (up in RA) or ventricular identity (up in
CT) showed an overlap between two or three lines (Fig-
ure 6D). Since the atrial- and ventricular-enriched CM
populations from the WT NKX-GFP line were not just
one subtype, we further studied the overlap of atrial (14
transcripts) and ventricular transcripts (7 transcripts) in
both COUP-KO lines based on a 2-fold change (Figure 6D).
Based on GEO expression profiles, we found strong atrial
and ventricular identities in respective groups, indicated
Figure 5. COUP-KO-derived CMs Function-
ally Resemble their WT Counterparts
(A) Representative action potentials (APs)
of G+/M+ CMs generated from RA-treated and
G+/M CMs from CT differentiations of WT
NKX-GFP, COUP-KO1, and COUP-KO 2 cells.
(B) Averaged maximum diastolic potential
(MDP), maximum AP amplitude (APAmax)
and AP plateau amplitude (APAplat),
maximum upstroke velocity (dV/dtmax), and
AP duration at 20%, 50%, and 90% repo-
larization (APD20, APD50, and APD90). n = 12
cells for WT NKX-GFP RA G+, n = 12 cells for
COUP-KO 1 RA G+/M+, and n = 14 cells for
COUP-KO 2 RA G+/M+; n = 13 cells for WT NKX-
GFP CT G+, n = 12 cells for COUP-KO 1 CT G+/
M, and n = 12 cells for COUP-KO 2 CT G+/M;
from three independent differentiations.
Data are displayed as means ± SEM; *p <
0.05.
See also Figure S6.by upregulation of ALDH1A2, TUBB2A, ZNF385B,
SLC9A3R1, ZNF533, and ADD3 in RA, and LAMB1 and
EMILIN2 in CT. These subtype-specific transcripts were
differently expressed between the COUP-KO lines and
the WT NKX-GFP line, but the majority (ZNF385B,
SLC9A3R1, ZNF533, and ADD3 in RA, as well as LAMB1
and EMILIN2 in CT) overlapped with the COUP-red
reporter, indicating that the COUP-TFII reporter line faith-
fully recapitulated atrial identity, which is not affected by
the loss of COUP-TFII. In addition, other transcripts with
an atrial identity could be identified in the individual
COUP-KO lines, but were lost in the common upregulated
pool since the 2-fold change cutoff was not met. For
example, the atrial-specific ion channel-encoding gene
KCNA5 exhibited a 2-fold enhanced expression in COUP-
KO 2, and a 1.7-fold upregulation in COUP-KO 1.
Role of COUP-TFI and COUP-TFII Isoforms during
Atrial Differentiation of WT and COUP-KO Lines
There is a high degree of homology and overlapping
expression patterns between COUP-TFII and COUP-TFI.
Moreover, we recently demonstrated that both COUP-TFs
similarly regulate atrial-specific potassium channel genes,
KCNA5 and KCNJ3 (Devalla et al., 2015). COUP-TFI gene
expression and protein levels were similar in WT NKX-
GFP and COUP-KO CMs, indicating that COUP-TFI expres-
sion does not compensate for the complete loss of COUP-
TFII expression (Figures S7A and S7B).To date, six different transcript variants of human COUP-
TFII have already been identified (Table S2). Structural
variant 1 (NR2F2-001, NM_021005) encodes full-length
COUP-TFII protein (isoform a) with 414 amino acids (aa)
and is composed of the typical elements of nuclear recep-
tors: an N-terminal ligand-independent activation domain
(activation function 1; aa: 1–79), followed by a highly
conserved DNA-binding domain (DBD) (aa: 80–144), and
a ligand-binding domain (LBD) (aa: 195–414) at the C-ter-
minal end (Figure S7C) (Achatz et al., 1997; Yamazaki et al.,
2013). Structural variants 2 (NR2F2-002, NM_001145155),
3 (NR2F2-201, NM_001145156), and 4 (NR2F2-003,
NM_001145157) encode truncated protein isoforms (iso-
forms b and c), which share the same LBD, but lack the
DBD domain (Figure S7C) (Achatz et al., 1997; Yamazaki
et al., 2013). Similarly, structural variant 5 has amajor trun-
cation, but at the C-terminal. In contrast, non-coding short
variant 6 is transcribed into amicroRNA. Since the predom-
inant transcript variant 1 of COUP-TFII is expressed pre-
dominantly in hESC-AMs and also because only variant 1
contains the transactivatingDBDdomain, sgRNAswere de-
signed to specifically recognize this isoform for theCRISPR/
Cas9 gene-editing strategy (Figure 1A). Since little is known
about COUP-TFII isoform expression in hESC-AMs or
hESC-VMs, we determined their expression by qPCR and
western blot in RA and CT cultures from WT NKX-GFP
and COUP-KO hESCs. Expression of all variants was
strongly induced by RA. No differences in regulation ofStem Cell Reports j Vol. 9 j 1765–1779 j December 12, 2017 1773
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gene expression were observed between WT NKX-GFP and
COUP-KO cells (Figure S7D). Correspondingly, western
blotting confirmed the differential expression pattern of
each COUP-TFII variant between RA and CT (Figure S7E).
Interestingly, after overexposure of the blots, we detected
enhanced expression of COUP-TFII isoform ‘‘c’’ primarily
after induction with RA in WT NKX-GFP and also COUP-
KO (Figure S7E). Two additional bands at 40 and 60 kDa
were also evident, which may correspond to unknown iso-
forms of COUP-TFII (Figure S7E). Following increased
exposure, we also identified low levels of COUP-TFII iso-
form a in CT condition from WT NKX-GFP, but not from
COUP-KO hESCs (Figure S7E). Since truncated COUP-TFII
variants b and c lack the DBD, it is unlikely that they
directly affect expression of COUP-TFII target genes,
although we cannot exclude these isoforms playing a role
in indirect transcriptional regulation and thereby compen-
sate for the loss of the dominant isoform a.
DISCUSSION
Efficient procedures to differentiate defined cardiac sub-
types from hPSCs are important for disease modeling and
drug screening. Previously, we demonstrated robust gener-
ation of atrial CMs and their application for predictive
pharmacology (Devalla et al., 2015). Although these
cultures were enriched for atrial CMs (80%–90%), other
subtypes were still present. Here, we therefore generated a
fluorescent human atrial stem cell reporter based on the
nuclear receptor COUP-TFII, which is predominantly ex-
pressed in human atrial, but not ventricular CMs (Devalla
et al., 2015). Specifically, we generated a dual fluorescent
NKX2.5EGFP/+-COUP-TFIImCherry/+ reporter line by target-
ing the human NKX-GFP hESC cardiac reporter (Elliott
et al., 2011) via CRISPR/Cas9-mediated genome editing.
RA treatment during differentiation of the COUP-red line
resulted in rapid induction of mCherry. This is consistent
with our previous data demonstrating that COUP-TFII
expression is rapidly increased in differentiating cardiac
progenitor cells within days of RA treatment (Devalla
et al., 2015). As expected, only upon induction with RA
does mCherry partially overlap with NKX2.5-GFP, indi-Figure 6. G+M+ CMs Lacking Functional COUP-TFII Exhibit Atrial C
(A and B) qPCR analysis of selected atrial or ventricular transcripts
populations from CT compared with G+ populations of WT NKX-GFP RA
Data are displayed as means ± SEM; *p < 0.05.
(C) Hierarchical clustering of G+/M+ RA fractions and G+/M CT fracti
similarity to their G+ WT NKX-GFP or G+/M+ and G+/M COUP-red equi
(D) Heatmaps: fold difference of atrial- and ventricular-enriched tran
expressed genes between RA (atrial transcripts, left panel) and CT (ven
COUP-red at a threshold of 2-fold difference.
See also Figures S6 and S7 and Table S3.cating COUP-TFII-expressing CMs. COUP-red hESCs
efficiently developed into contracting CMswith functional
sarcomeres. Transcriptional and functional characteriza-
tion of G+/M+ CMs established their atrial phenotype,
demonstrating that this COUP-red dual reporter line reli-
ably captures cells that are directed towards the atrial CM
lineage.
Modulating RA signaling upon mesoderm induction has
been demonstrated to guide differentiation towards epicar-
dial cells, which subsequently undergo epithelial-to-
mesenchymal transition to epicardial-derived smooth
muscle cells (Iyer et al., 2015). Moreover, COUP-TFII is
expressed in venous endothelial, as well as smooth muscle
cells (You et al., 2005). In agreement with these findings,
the majority of mCherry-positive non-CMs (G/M+)
displayed a smooth muscle-like profile, as indicated by
transcriptional profiling, as well as the expression analysis
of smooth muscle cell and endothelial markers.
Inmice, homozygous loss of COUP-TFII resulted in lethal
hemorrhages and edema formation in neural and myocar-
dial tissues (Pereira et al., 1999). Homozygous deletion or
myocardial specific deletion of COUP-TFII have been
demonstrated to severely affect development of both atria
during early embryonic development (Pereira et al., 1999;
Wu et al., 2013). While primitive atrial chambers of
COUP-TFII mouse mutants had a similar size compared
with WT littermates during early phase of development,
loss of COUP-TFII impeded rightward expansion of the
common atrium (Pereira et al., 1999). Tissue-specific dele-
tion of COUP-TFII forced CMs of the atrial chambers to
acquire morphological and functional characteristics
typical of ventricular cells (Wu et al., 2013). These findings
suggest an important role for COUP-TFII inmaintaining an
atrial fate, while simultaneously suppressing a ventricular
phenotype. In accordance, we had shown in differentiated
hESC-AMs that COUP-TFII is able to bind to the promoters
of atrial-specific ion channel genes KCNA5 and KCNJ3 and
regulates their expression in hESC-derived CMs (Devalla
et al., 2015). We investigated here the atrial differentiation
potential of hESCs after CRISPR/Cas9-mediated inactiva-
tion of both COUP-TFII alleles. We successfully derived
functionally contractingCMs from these COUP-KOhESCs.haracteristics on Transcriptional Level
of sorted COUP-KO 1 derived G+/M+ fractions from RA and G+/M
and CT differentiations at D14 (n = 4 independent differentiations).
ons of two independent subclones COUP-KO 1 and 2 revealed high
valents.
scripts with Venn diagrams to display the overlap of differentially
tricular transcripts, right panel) in COUP-KO 1, 2, and WT NKX-GFP or
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As indicated by similar percentages of NKX2.5-GFP-posi-
tive CMs, onset and overall efficiency of atrial differentia-
tion were not affected by complete deletion of COUP-
TFII. Morphological characterization of EBs from either
RA or CT differentiations revealed high similarity to their
equivalent WT NKX-GFP EBs throughout the whole differ-
entiation procedure. Electrophysiological characterization
somewhat surprisingly demonstrated clear atrial identity
of G+/M+ CMs. In accordance, the global transcriptional
profile of G+/M+ CMs derived from COUP-KO hESCs was
very similar to that of hESC-AMs derived from WT NKX-
GFP, as well as the heterozygous COUP-red atrial reporter,
with upregulation of atrial-enriched genes and downregu-
lation of ventricular-enriched genes. Only a very small
group of genes were differentially expressed between CMs
from both COUP-KO lines and WT NKX-GFP CMs. To
confirm this, we determined expression levels of various
genes that have previously been shown to be direct targets
of COUP-TFII by qPCR. These atrial- or ventricular-specific
candidates showed similar expression patterns in COUP-
KO and WT NKX-GFP CMs. Of all of these COUP-TFII
target genes, only KCNJ5, encoding the atrial-specific in-
ward rectifier potassium channel 4 (Kir3.4), was decreased
in the heterozygous COUP-red reporter and even further
after complete KO of COUP-TFII, although this was not
evident from whole-genome profiling by microarray.
Kir3.4 subunits form functional heteromeric ion channels
only after assembly with Kir3.1 subunits, which are en-
coded by KCNJ3. In correspondence to the transcriptional
profile, AP properties of either G+/M+ or G+/M CMs
derived fromCOUP-KO cells were identical to those of their
WT equivalents. Together these findings suggested that
COUP-TFII might not be essential for RA-induced atrial
CM differentiation or for suppression of the ventricular
phenotype in hPSCs. Previously, we had shown that short
hairpin RNA (shRNA)-mediated knockdown of COUP-TFs
in hESC-derived CMs resulted in a change of gene expres-
sion of KCNA5, KCNJ3, and KCNJ5 (Devalla et al., 2015).
The difference in COUP-TFII-dependent gene regulation
with respect to KCNA5 and KCNJ3 between COUP-TFII
KO and knockdown may reflect a higher non-specific off-
target effect of shRNAs (Schulte-Merker and Stainier,
2014). Alternatively, differences in acute versus chronic
gene disruption may contribute to the observed difference
(Rossi et al., 2015). Whereas acute effects were studied
following COUP-TFII knockdown in day 30 atrial CMs pre-
viously, in the present study we analyzed gene expression
in sorted CMs, which had a complete loss of COUP-TFII
already from the start of differentiation.
Besides a high degree of homology between COUP-TFII
and COUP-TFI (NR2F1), these two nuclear receptors also
have overlapping expression patterns in human fetal, as
well adult hearts (Devalla et al., 2015). Knockout of1776 Stem Cell Reports j Vol. 9 j 1765–1779 j December 12, 2017COUP-TFII did not lead to increased levels of COUP-TFI,
suggesting that it is not likely that COUP-TFI compensates
for the loss of COUP-TFII. Nevertheless, we cannot exclude
redundancy and the possibility that COUP-TFI levels may
be sufficient to initiate and complete atrial differentiation
in hPSCs. Interestingly, in addition to the predominant
COUP-TFII isoform a,we detected isoform c predominantly
in RA-treated and not in CT samples. Even though isoform
a is predominant, it is possible that COUP-TFII variants b
or c, which lack the DBD, may affect atrial differentiation
via a mechanism independent of direct gene regulation.
However, so far this mechanism of action has not been
described for COUP-TFII. Interestingly, isoforms a and b,
but not c, have identical orthologs in mouse.
Although various de novo or inherited mutations,
including missense mutations of human COUP-TFII have
been related to atrioventricular septal defects and other
congenital heart defects, such as tetralogy of Fallot, aortic
stenosis, coarctation of the aorta, hypoplastic left heart
syndrome, and ventricular septal defects, loss-of-function
mutations in COUP-TFII have not been implicated as
contributing to atrial defects exclusively (Al Turki et al.,
2014).
Even though hPSC ventricular CMs have been used suc-
cessfully to recapitulate a variety of cardiac disease pheno-
types and drug-induced toxicities, less attention has been
paid to diseasemodeling using hPSC atrial CMs. Previously,
a bacterial artificial chromosome reporter construct, in
which expression of a fluorescence is driven by expression
of the atrial-specific gene sarcolipin, has been described
and used for identification of hPSC atrial CMs (Josowitz
et al., 2014). However, enhanced Sarcolipin expression
was also detected in CMs of ventricles with reduced systolic
function (Zheng et al., 2014), and is also highly expressed
in non-CMs, such as human skeletal muscle (Minamisawa
et al., 2003). As mentioned previously, COUP-TFII is also
expressed in other non-atrial cell types and tissues. These
are important factors to consider for the proper use of line-
age reporters.
Selection of hPSC-AMs is crucial for gaining mechanistic
insights into processes underlying atrial specification of
hPSCs during differentiation in vitro and will improve
understanding of cardiac diseases specially affecting atrial
CMs, as well as identifying atrial-specific surface markers.
Because cardiac differentiation of different hPSC lines is
not equally efficient, identification of atrial-specific surface
markers would allow purification of atrial CMs generated,
for example, from patient-specific induced pluripotent
stem cells to model atrial-specific (genetic) disorders, such
as atrial fibrillation in vitro. A precedent for this approach
was the identification of SirpA and VCAM1 as surface
markers for NKX2.5-expressing CMs using the
NKX2.5EGFP/+ hESC line (Elliott et al., 2011).
In summary, we have generated a dual NKX2.5EGFP/+-
COUP-TFIImCherry/+ hPSC line, which allows the identifica-
tion and selection of functional atrial CMs. Furthermore,
we showed that COUP-TFII is dispensable for acquiring
an atrial phenotype during RA-directed differentiation of
hESCs. Most importantly, this unique reporter line, which
allows selection of hESC-AMs, will be a valuable tool for
studying atrial differentiation, disease modeling, and early
drug screening. Selected populations of hESC-AMs will
impact optimization and standardization for hPSC-depen-
dent assays, facilitate studies related to underlying mecha-
nisms of atrial-specific diseases, and advance the develop-
ment of new strategies to cure underlying causes of
certain cardiac disease.EXPERIMENTAL PROCEDURES
Maintenance of hESCs
hESCs were maintained as undifferentiated colonies either in
Essential 8 medium on vitronectin (Gibco, Thermo Fisher Scienti-
fic), or on irradiatedmouse embryonic fibroblasts in hESCmedium
(Devalla et al., 2015).
Vector Construction
The sgRNAs (sgRNAs 1–3) were designed either with the web tool
CRISPR Design (http://crispr.mit.edu) or Benchling (https://
benchling.com/crispr). Oligos containing the sgRNA sequences
(Integrated DNA Technologies) were cloned into the pSP-
Cas9(BB)-2A-puro vector (PX459; Addgene) as described previ-
ously (Ran et al., 2013). The COUP-TFII-mCherry targeting vector
was generated in three steps. See Supplemental Experimental
Procedures for extended description and sequences.
hESC Transfection
A total of 0.25–1.0 3 106 hESCs was simultaneously transfected
with 1.6–4 mg PX459-sgRNA vector and either 2 mg COUP-TFII-
mCherry targeting vector or 8 pmol of the 110 bp COUP-TFII
WT ss-oligo (synthesized as an Ultramer from IDT) using Lipofect-
amine 2000 (Invitrogen) according tomanufacturer’s instructions.
Additional information, vector maps, and sequences are available
in the Supplemental Experimental Procedures.
Genomic DNA Isolation, PCR Screening, and
Sequencing
Genomic DNAwas extracted from the transfected hESCs using the
QuickExtract DNA Extraction Solution (EpiCentre). Correctly
modified clones were identified by PCR-based screening strategies
using PlatinumHigh Fidelity TaqDNApolymerase (Gibco, Thermo
Fisher Scientific) followed by Sanger sequencing of the PCR prod-
uct (Macrogen). See the Supplemental Experimental Procedures
for primer sequences.
Cardiac Differentiation of hESCs
Differentiation to hESC-derived CMs was performed using a previ-
ously described spin-EB protocol (Devalla et al., 2015).Microscopy and Video Acquisition
Bright-field and fluorescent images or videos at 103magnification
were acquiredwith a Leica AF-6000LXmicroscope (LeicaMicrosys-
tems) with controlled temperature and CO2.
Flow Cytometry
D7 EBs were dissociated with 13 TrypLe Select and D14 EBs with
103 TrypLe Select and percentages of G+/M, G/M+, double-pos-
itive, or double-negative cells were immediately quantified with a
MACSQuant VYB flow cytometer (Miltenyi Biotech). See the Sup-
plemental Experimental Procedures for extended description on
antibodies.
FACS
G+/M+were purified into four populations using a BD ARIA III flow
cytometer after exclusion of dead cells and debris according to side
and forward scatter. After sorting, cells were immediately lysed for
RNA isolation or re-plated for functional analysis onto Matrigel-
coated glass coverslips into TID medium (Birket et al., 2015).
Transcriptional Analysis
Microarrays were performed on Human HT-12 v4 Expression Bead
Chips at ServiceXS, and analysis was performed with GeneSpring
GX (Agilent Technologies). qPCRwas carried out using SYBRGreen
(Applied Biosystems) and the CFX384 real-time PCR detection
system. Statistical analysis was carried out with GraphPad Prism 7.
Ordinary one-way ANOVAwith Tukey’s multiple comparisons test
was applied for differences in means between groups. Data are
expressed as means ± SEM. Statistical significance was defined as
p < 0.05. GO was performed using DAVID (https://david.ncifcrf.
gov) (Huang et al., 2008, 2009). Additional information can be
found in the Supplemental Experimental Procedures.
Cellular Electrophysiology
APs were recorded at 36C ± 0.2Cusing the amphotericin-B perfo-
rated patch-clamp in silico technique (Giles and Noble, 2016;
Hoekstra et al., 2012; Meijer Van Putten et al., 2015). An in silico
inward rectifier K+ current with kinetics of Kir2.1 channels was in-
jected through a dynamic clamp to overcome the depolarized state
of the cells. See the Supplemental Experimental Procedures for an
extended description. Data are presented as means ± SEM. Statisti-
cal analysis was carried out with SigmaStat 3.5 software. Normality
and equal variance assumptions were tested with the Kolmogorov-
Smirnov and the Levene median tests, respectively. Two groups
were compared with unpaired t test or, in case of a failed normality
and/or equal variance test, Mann-Whitney rank-sum test. More
than two groups were compared using one-way ANOVA followed
by a Student-Newman-Keuls method post hoc test. In case of non-
normally distributed parameters, Kruskal-Wallis test followed by
pairwise comparisons with Dunn’s method was performed p <
0.05 was considered statistically significant.
Immunostaining and Confocal Imaging
Cells were stained for troponin I, mCherry, SMA, PECAM, or AFP,
using primary antibodies followed by secondary conjugated anti-
bodies to Alexa Fluor 647, 555, or Cy-3. Confocal images wereStem Cell Reports j Vol. 9 j 1765–1779 j December 12, 2017 1777
analyzed using Leica Microsystems. See the Supplemental Experi-
mental Procedures for extended description.
Western Blot
For western blotting, samples were lysed in standard RIPA buffer,
and 100 mg protein was analyzed on an 8% polyacrylamide gel.
For detection, mouse IgG anti-COUP-TF I (1:500; Perseus Prote-
omics), mouse IgG anti-COUP-TFII (isoform a; 1:500; Perseus
Proteomics), rabbit IgG anti-COUP-TFII (isoform a + b + possible
c, 1:500; clone D16C4, Cell Signaling Technology), rabbit IgG
anti-GAPDH (1:500; Millipore), and mouse IgG anti-a-actinin
(A7811, Sigma-Aldrich) were used in combination with the corre-
sponding secondary antibodies goat anti-mouse- or anti-rabbit-
IgG HRP (1:2,000; Cell Signaling Technology).
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